Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2015 / Article
Special Issue

Herbal Medicine after Interventional Therapy in Cardiovascular Diseases: Efficacy, Mechanisms, and Safety

View this Special Issue

Research Article | Open Access

Volume 2015 |Article ID 828427 | https://doi.org/10.1155/2015/828427

Wei Liu, Lingyan Wang, Jiahui Yu, Patrick Fordjour Asare, Ying-Qiang Zhao, "Gastrodin Reduces Blood Pressure by Intervening with RAAS and PPARγ in SHRs", Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 828427, 8 pages, 2015. https://doi.org/10.1155/2015/828427

Gastrodin Reduces Blood Pressure by Intervening with RAAS and PPARγ in SHRs

Academic Editor: Honglin Luo
Received02 Mar 2015
Revised15 Jul 2015
Accepted11 Oct 2015
Published26 Oct 2015


Gastrodin is a bioactive compound extracted from traditional Chinese medicine, Gastrodia elata  Bl. It has a definite effect on reducing blood pressure in hypertensive patients. However, the mechanisms of gastrodin in lowering blood pressure still remain unclear. In this study, 4 weeks of administration of gastrodin (100 mg/kg/d intraperitoneally injected) decreased the systolic blood pressure (SBP) in spontaneously hypertensive rats (SHRs) ( versus , ). Among SHRs receiving gastrodin treatment, angiotensin II (Ang II) and aldosterone (ALD) in serum were significantly decreased ( versus , versus , and , , resp.) and dramatically downregulated expression of angiotensin type 1 receptor (AT1R) ( versus , ) in myocardium in both mRNA and protein levels compared with their corresponding groups without gastrodin treatment. Additionally, gastrodin increased the mRNA expression ( versus , ) and protein synthesis ( versus , ) of peroxisome proliferator-activated receptor γ (PPARγ) in myocardium tissues. Overall, our data demonstrated that gastrodin was able to decrease the SBP in SHR. Furthermore, this study showed that gastrodin intervened with the renin-angiotensin-aldosterone system (RAAS) and PPARγ effectively, which indicates its antihypertensive mechanism.

1. Introduction

As one of the most common chronic diseases in the world, hypertension accelerates the progression of cardiovascular disease and severely threatens human health. It has been shown that the renin-angiotensin-aldosterone system (RAAS) plays a major role in the initiation and progression of hypertension [1]. RAAS is a cascade with effector molecules such as angiotensin II (Ang II) and aldosterone (ALD). Ang II has a strong biological activity in constricting blood vessels, enhancing aldosterone secretion, and ultimately elevating blood pressure level. Aldosterone enhances the reabsorption of sodium and water, thus increasing blood volume and blood pressure [2]. Therefore, inhibiting the activation of RAAS is one of the main strategies to lower blood pressure in patients with hypertension.

Peroxisome proliferator-activated receptor (PPAR) γ is a nuclear transcription factor regulated by ligands which are expressed in the cardiovascular system [3]. It has been reported that PPARγ can regulate the gene expression related with RAAS and may play a regulatory role in blood pressure modulation [4].

Gastrodin (PubChemCID:115067(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[4-(hydroxymethyl)phenoxy]oxane- 3,4,5-triol, Figure 1) is one of the major bioactive components extracted from the Chinese herb Gastrodia elata Bl. (Figure 1). Gastrodin injection has been extensively used to treat cardiovascular and cerebrovascular diseases in China and has a certain efficacy to lower blood pressure in hypertensive patients [5]. However, the related mechanisms still remain cryptic. Therefore, we aimed to determine whether gastrodin could attenuate blood pressure by regulating RAAS and PPARγ. It is important to note that gastrodin is used clinically to manage cardiovascular disease and that the heart is the main target organ in the management of cardiovascular diseases. In this regard, we used echocardiography to evaluate cardiac function after gastrodin treatment.

Clinical and experimental evidence suggests that cardiac renin-angiotensin system (RAS) plays an important role in the regulation of SBP. Of note, PPARγ expression occurs in the heart and has been shown to possess key regulatory function on the cardiac RAS expression level. Our explicit objective was to study the biological action of gastrodin and its therapeutic significance on the regulation of PPARγ, ACE, and AT1R in the heart. We found that activation of cardiac PPARγ correlated with reduced expression level of myocardial ACE and AT1R expression levels. The subsequent reduction in blood pressure level suggests that gastrodin could reduce blood pressure by elevating the expression of PPARγ which negatively regulates cardiac ACE and AT1R.

2. Materials and Methods

2.1. Animals and Treatment

Ten-week-old male Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHRs) were obtained commercially from Vital River Laboratories, Beijing, China. SHRs were randomly divided into model (SHR) and treatment groups (GAS) with 8 rats in each group. Eight WKY belonged to the control group (WKY). Rats were housed in a controlled environment (°C and 50%  ±  5% humidity) receiving a circadian rhythm of 12 h/12 h light/dark. Rats were allowed food and water ad libitum. Bedding was refreshed daily for every cage. The first two weeks was the adaptation period, and rats were not given any intervention. Gastrodin therapy started from the third week during which rats were under therapeutic treatment. SHRs in the treatment group were injected intraperitoneally with gastrodin at the dose of 100 mg/(kg·d) for 4 weeks. The dose of gastrodin administration was arrived at by critical assessment of clinical dosage and analysis of previous studies [6]. Body weight and blood pressure of the rats were measured every week. All the procedures were approved by the Animal Ethics Review Committee of Tianjin University of Traditional Chinese Medicine.

2.2. Reagents

Gastrodin injections were purchased from Hainan Helpson Medicine & Biotechnique Co., Ltd. The concentration of gastrodin was 100 mg/mL, and it was stable for 2 years at room temperature. ELISA kit of aldosterone and angiotensin II were purchased from Beijing Sino-UK Institute of Biological Technology. Western blot reagents were purchased from Sigma, while antibodies were purchased from Santa Cruz. Real-time quantitative PCR reagents were purchased from Tianjin Hao Yang Biological Manufacture Co., Ltd., and the primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd.

2.3. Monitoring of Blood Pressure, Heart Rate, and Body Weight

Blood pressure (systolic blood pressure), heart rate, and body weight of rats were monitored once a week. Systolic blood pressure (SBP) and heart rate were monitored by the noninvasive tail-cuff method using animal sphygmomanometer (BP98AWU, Softron, Japan). All the blood pressure and heart rate measurements were performed on conscious animals. For each SHR and WKY rat, blood pressure and heart rate were measured with multiple readings, until 15 stable measurements in a row were obtained. Data were calculated as an average of blood pressure and heart rate values.

2.4. Cardiac Function Study by Echocardiography

Echocardiography was done by an observer blinded to the experiment, and measurements were taken before sacrifice. Echocardiography was performed by Visual Sonics Vevo 2100 imaging system. The LV was assessed in both parasternal long-axis and short-axis views at a frame rate of 50 Hz. End-systole or end-diastole was defined as the phase in which the smallest or largest area of LV, respectively, was obtained. Left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) were measured from the LV M-mode tracing with a sweep speed of 50 mm/s at the mid-papillary muscle level. These parameters were used to determine left ventricular ejection fraction.

2.5. Serum Collection and Harvest of the Tissue

After abdominal anesthesia in rats with chloral hydrate (5%, 6 mL/kg, i.p.), blood samples were collected via abdominal aorta puncture. Serum was then prepared by centrifugation of the collected blood (2000 rpm for 20 min). Serum samples were stored at −80°C and used to determine the levels of aldosterone (ALD) and angiotensin II (Ang II) with ELISA kits in a blinded manner following the manufacturer’s instructions. Heart was removed from each rat.

2.6. Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) Analysis

Total RNA was isolated from the myocardium tissues ( per group) using TRIZOL reagent (Tianjin Hao Yang Biological manufacture Co., Ltd., China). RNA was reverse-transcribed using SuperScript First Strand cDNA System (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.

The following primer sequences were used: β-actin (NM_031144), forward (TCA GGT CAT CAC TAT CGG CAA), reverse (AGC ACT GTG TTG GCA TAG AGG), ACE (NM_012544.1), forward (AAC AGG TTC GTG GAG GAG TAT), reverse (CAG GTG CCA TAT TTC AAG GTA). AT1R (NM_030985.4), forward (ATC TCG CCT TGG CTG ACT TAT), reverse (GAA GGA ACA CAC TGG CGT AGA), and PPARγ (NM_001145366.1), forward (AAG GGT GCC AGT TTC GAT CC), reverse (TAT TCA TCA GGG AGG CCA GCA). The sizes of the PCR products amplified with the primers were β-actin, 169 bp, ACE, 161 bp, AT1R, 150 bp, and PPARγ, 159 bp, respectively. In preliminary experiments, we confirmed that the efficiency of these primer pairs is comparable (data not shown). qRT-PCR was done using SYBR Green PCR master mix (Applied Biosystems) in a total volume of 20 μL on the 7900HT fast real-time PCR system (Applied Biosystems) as follows: 95°C for 15 min, 40 cycles of 95°C for 20 s, and 57°C for 20 s. A dissociation procedure was performed to generate a melting curve for confirmation of amplification specificity. β-actin was used as the reference gene. The relative levels of gene expression were represented as , and the fold change of gene expression was calculated by the method [7].

2.7. Western Blotting Assay

Western blotting assay was performed to determine protein expression of AT1R and PPARγ ( per group). The myocardium tissue was homogenized in the lysis buffer using an ultrasound homogenizer at 50 Hz. The lysate was then centrifuged. The protein concentration of the supernatant was measured with the Bradford protein assay. Proteins were loaded into 8% SDS-polyacrylamide gels and transferred to PVDF membranes. After blocking in nonfat milk, the membranes were exposed to a rabbit polyclonal antibody against AT1R or PPARγ or β-actin overnight at 4°C. After incubation with HRP-linked secondary antibodies, the immune complexes were visualized with chemiluminescence (ECL Blotting Analysis System; Amersham, Arlington Heights, IL) and exposed to X-ray film, measured with Image J software, and normalized to β-actin.

2.8. Statistical Analysis

All results were expressed as mean ± S.E.M. Statistical comparisons between different groups were performed by one-way ANOVA with Dunnett’s multiple comparison posttest. Differences with value less than 0.05 were considered statistically significant.

3. Results

3.1. General Health of Rats in Each Group

Gastrodin did not significantly affect the body weight of the rats in this study; however, all rat weights increased during the experimental period. WKY’s weights were more than the other two groups from the beginning to the end of the study. All the differences were statistically significant (Figure 2). Daily intraperitoneal injection of gastrodin did not affect food consumption (Figure 3). Moreover, gastrodin did not affect heart rate (Figure 4).

3.2. Systolic Blood Pressure

At the baseline, the systolic blood pressure (SBP) was no different than SHR and GAS. After two weeks of treatment, SBP of GAS began to reduce and was significantly decreased compared with SHR (). There was also a recorded steady reduction of SBP in GAS treated group, while elevated level of SBP in SHR was observed. Throughout the experiment, SBP of WKY was lower than in SHR and GAS () (Figure 5). The data about the effects of gastrodin in the normotensive rats are not shown. First of all, there was no significant difference in the indices on the normotensive rats after daily administration of gastrodin injection.

3.3. Cardiac Function

After four weeks of treatment, there was no significant difference in cardiac function among the three groups (Table 1).

IVS; d (mm)IVS; s (mm)LVID; d (mm)LVID; s (mm)LVPW; d (mm)LVPW; s (mm)EF (%)

WKY1.29 ± 0.072.21 ± 0.296.35 ± 0.433.77 ± 0.581.64 ± 0.152.48 ± 0.1669.95 ± 8.40
SHR1.70 ± 0.182.33 ± 0.376.24 ± 0.804.42 ± 1.232.02 ± 0.262.41 ± 0.4755.16 ± 17.32
GAS1.53 ± 0.242.09 ± 0.226.73 ± 0.424.88 ± 0.491.87 ± 0.252.35 ± 0.2151.95 ± 7.87

After 4-week treatment, there was no difference in cardiac function among the three groups.

3.4. Effects of Gastrodin on RAAS

Since gastrodin showed effect on SBP in SHR, we explored the possible mechanisms. Previous studies have shed more light on the role RAAS plays in regulating blood pressure levels. In this regard, we sought to determine the effects of gastrodin on RAAS in vivo. After four weeks of treatment, the serum level of Ang II in GAS was lower than in SHR (). Surprisingly, the Ang II serum level in GAS was also lower than in WKY (Figure 6(a)). Gastrodin also significantly reduced ALD level in serum compared with SHR (). There was no significant difference between WKY and GAS treatment groups in the serum level of ALD (Figure 6(b)).

We further examined the mRNA expression of ACE and AT1R by qRT-PCR. After four weeks of treatment, compared with SHR, the mRNA expression of ACE in GAS declined, but the difference was not statistically significant (Figure 7(a)). Meanwhile, the mRNA expression of AT1R was lower in GAS than in SHR, and the difference was statistically significant () (Figure 7(b)). There was no significant difference in mRNA expression levels of ACE and AT1R between WKY and GAS groups (Figures 7(a) and 7(b)). Next, we examined the protein level of AT1R in myocardium by western blotting. The protein level of AT1R in GAS was significantly lower than in SHR (), while it was relatively higher compared with WKY (Figure 8).

3.5. Effects of Gastrodin on PPARγ

Considering that PPARγ had relevance with RAAS, we further examined the mRNA expression and protein level of PPARγ in myocardium.

After four weeks of treatment, the mRNA expression of PPARγ in GAS was higher than in SHR (). And it was lower than in WKY () (Figure 9(a)).

Through western blotting, the protein level of PPARγ in GAS was significantly higher than in SHR (), while it was relatively lower compared with WKY (Figure 9(b)).

4. Discussion

Gastrodin is the main active ingredient obtained from the Chinese herb, Tianma (Gastrodia elata Bl.) [810]. Gastrodin is considered to have several beneficial properties. Gastrodin has been suggested to be effective as an anticonvulsant and analgesic and is a sedative effective against vertigo, general paralysis, epilepsy, and tetanus [11]. Clinical studies have shown that gastrodin has a good effect on treatment of vertigo and was able to improve hemodynamics, which quickly eliminated dizziness, vertigo, nausea, vomiting, tinnitus, and other symptoms caused by cervical spondylosis and atherosclerosis. Besides, gastrodin may improve microcirculation and cardiovascular compliance and promote fibrinolytic activity and anti-ischemic-reperfusion injury [12]. Additionally, gastrodin could also improve blood pressure, blood rheology, endothelin, and other indicators in patients with hypertension [5]. Some studies have shown that gastrodin inhibited cardiac hypertrophy and fibrosis through inhibiting ERK1/2 signaling pathway and activation of GATA-4 [6]. This study examined the effect of gastrodin on SBP and elucidated its possible mechanism via the activation of PPARγ.

Our investigation showed that treatment with gastrodin for 4 weeks was able to lower the SBP in SHR and did not affect the general health of rats, including body weights, food consumption, and heart rate. The reduction of SBP by gastrodin was associated with the remarkable increase in the level of cardiac PPARγ and the subsequent reduction of the hypertensive effects of ACE and AT1R which can also be locally synthesized in the heart.

Renin-angiotensin-aldosterone system (RAAS) is an important factor in regulating blood pressure, within which there exists a proteolytic cascade. Circulating renin cleaves its substrate angiotensinogen to form the decapeptide angiotensin I (Ang I), which is converted by angiotensin-converting enzyme (ACE) to angiotensin II (Ang II). As the main mediator of RAAS, Ang II acts as a vasoconstrictor and thus elevates blood pressure. It also stimulates the release of aldosterone (ALD) which mediates sodium and water retention by directly acting at the distal tubule and eventually elevating the blood pressure level. The function of Ang II is mediated by the plasma membrane receptor AT1 (AT1R). AT1R stimulates vasoconstriction, vascular cell hypertrophy and hyperplasia, sodium retention, and reactive oxygen species generation. Furthermore, Ang II interacts with AT1R, which results in left ventricular remodeling, alterations in the morphology and mechanical properties of the vasculature, and the development of endothelial dysfunction [1, 13]. Thus, our finding that gastrodin improves blood pressure by targeting and inhibiting Ang II, ALD, ACE, and AT1R does not only have therapeutic significance in clinical management of hypertensive patients; but it may also enhance our understanding on the molecular mechanism underlying the antihypertensive effect of the traditional Chinese medicine.

As aforementioned, ACE, Ang II, AT1R, and ALD are the most important components in RAAS. In our study, we showed that gastrodin could reduce the concentration of Ang II and ALD in serum (Figures 6(a) and 6(b)), decrease the mRNA expression of AT1R (Figure 7(b)), and lower the protein level of AT1R (Figure 6). Surprisingly, gastrodin did not improve the cardiac function in spite of its effect on the expression of the abovementioned proteins (Table 1). It is possible that the intervention time was too short, which only brought changes in the level of protein molecules, and was not enough to cause changes in tissue function.

Peroxisome proliferator-activated receptor (PPAR) γ is a nuclear hormone receptor [14]. PPARγ is trans-activated by its agonists that have been reported to be able to lower blood pressure [1518]. Some clinical studies have shown that the PPARγ agonist telmisartan could inhibit ACE and block AT1R [19, 20]. Besides, PPARγ agonist also blocked the action of Ang II [19, 21]. PPARγ ligands such as rosiglitazone could also reduce the blood pressure in hypertensive rats, increase urinary aldosterone excretion, reduce heart-to-body weight ratio, and diminish aldosterone-induced heart hypertrophy [22]. Therefore, PPARγ not only downregulates the expression of ACE and AT1R, but also blocks the action of Ang II and ultimately inhibits adrenal aldosterone synthesis/secretion.

Therefore our findings suggest that the activation of PPARγ by gastrodin inhibited the expression of ALD and Ang II that led to the reduction in SBP level.

We found that gastrodin was able to increase the mRNA expression of PPARγ, as well as increasing its protein synthesis (Figures 7(a) and 7(b)). Thus, we do not rule out the possibility that gastrodin could reduce blood pressure by activating PPARγ target, since activated PPARγ intervenes with the important components of RAAS, such as ACE, Ang II, AT1R, and ALD. What is more, clinical studies have demonstrated that gastrodin can improve the blood pressure level in patients with hypertension. This study was designed to explore the mechanism of lowering blood pressure. With regard to this, we did not include positive controls in this experiment. Although gastrodin may lower blood pressure by inhibiting RAAS, it can be inferred from our data that the inhibition was not strong enough to improve the overall cardiac function. This can be partially attributed to gastrodin’s limited inhibition of RAAS which needs further investigation.

5. Conclusion

Despite our incomplete understanding of mechanisms involved in beneficial effects of gastrodin, the results of this study clearly demonstrated that gastrodin injected intraperitoneally at the dose of 100 mg/(kg·d) for 4 weeks decreased the SBP in SHR. Furthermore, this study showed that gastrodin intervened with RAAS effectively, including lowering the levels of Ang II and ALD in serum, reducing the mRNA expression of AT1R in myocardium, and decreasing the protein synthesis of AT1R. Meanwhile, gastrodin also increased the mRNA expression of PPARγ and its protein synthesis. According to previous studies, PPARγ could regulate RAAS and has antihypertensive effects. Therefore, the antihypertensive mechanism of gastrodin may be attributable to the direct intervention of RAAS, or indirect inhibition of RAAS via activation of PPARγ. This needs to be further explored.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


The authors are thankful for the financial support from National Natural Science Foundation of China (81273941/H2902).


  1. A. C. Simões E Silva and J. T. Flynn, “The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease,” Pediatric Nephrology, vol. 27, no. 10, pp. 1835–1845, 2012. View at: Publisher Site | Google Scholar
  2. H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama, “The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease,” Pharmacological Reviews, vol. 59, no. 3, pp. 251–287, 2007. View at: Publisher Site | Google Scholar
  3. S. Z. Duan, C. Y. Ivashchenko, M. G. Usher, and R. M. Mortensen, “PPAR-gamma in the cardiovascular system,” PPAR Research, vol. 2008, Article ID 745804, 10 pages, 2008. View at: Publisher Site | Google Scholar
  4. A. Sugawara, A. Uruno, K. Matsuda et al., “Effects of PPARγ agonists against vascular and renal dysfunction,” Current Molecular Pharmacology, vol. 5, no. 2, pp. 248–254, 2012. View at: Publisher Site | Google Scholar
  5. Q. Zhang, Y.-M. Yang, and G.-Y. Yu, “Effects of gastrodin injection on blood pressure and vasoactive substances in treatment of old patients with refractory hypertension: a randomized controlled trial,” Journal of Chinese Integrative Medicine, vol. 6, no. 7, pp. 695–699, 2008. View at: Publisher Site | Google Scholar
  6. C. Shu, C. Chen, D.-P. Zhang et al., “Gastrodin protects against cardiac hypertrophy and fibrosis,” Molecular and Cellular Biochemistry, vol. 359, no. 1-2, pp. 9–16, 2012. View at: Publisher Site | Google Scholar
  7. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at: Publisher Site | Google Scholar
  8. N. Li, K.-J. Wang, J.-J. Chen, and J. Zhou, “Phenolic compounds from the rhizomes of Gastrodia elata,” Journal of Asian Natural Products Research, vol. 9, no. 4, pp. 373–377, 2007. View at: Publisher Site | Google Scholar
  9. X.-D. Yang, J. Zhu, R. Yang, J.-P. Liu, L. Li, and H.-B. Zhang, “Phenolic constituents from the rhizomes of Gastrodia elata,” Natural Product Research, vol. 21, no. 2, pp. 180–186, 2007. View at: Publisher Site | Google Scholar
  10. Y.-Q. Xiao, L. Li, X.-L. You, B.-L. Bian, X.-M. Liang, and Y.-T. Wang, “A new compound from Gastrodia elata Blume,” Journal of Asian Natural Products Research, vol. 4, no. 1, pp. 73–79, 2002. View at: Google Scholar
  11. L. M. Ojemann, W. L. Nelson, D. S. Shin, A. O. Rowe, and R. A. Buchanan, “Tian ma, an ancient Chinese herb, offers new options for the treatment of epilepsy and other conditions,” Epilepsy and Behavior, vol. 8, no. 2, pp. 376–383, 2006. View at: Publisher Site | Google Scholar
  12. Y. Liu, X. Tang, J. Pei, L. Zhang, F. Liu, and K. Li, “Gastrodin interaction with human fibrinogen: anticoagulant effects and binding studies,” Chemistry—A European Journal, vol. 12, no. 30, pp. 7807–7815, 2006. View at: Publisher Site | Google Scholar
  13. C. R. Esther Jr., E. M. Marino, T. E. Howard et al., “The critical role of tissue angiotensin-converting enzyme as revealed by genetargeting in mice,” The Journal of Clinical Investigation, vol. 99, no. 10, pp. 2375–2385, 1997. View at: Publisher Site | Google Scholar
  14. S. A. Kliewer, H. E. Xu, M. H. Lambert, and T. M. Willson, “Peroxisome proliferator-activated receptors: from genes to physiology,” Recent Progress in Hormone Research, vol. 56, pp. 239–263, 2001. View at: Publisher Site | Google Scholar
  15. C. Marchesi and E. L. Schiffrin, “Peroxisome proliferator-activated receptors and the vascular system: beyond their metabolic effects,” Journal of the American Society of Hypertension, vol. 2, no. 4, pp. 227–238, 2008. View at: Publisher Site | Google Scholar
  16. T. D. Giles and G. E. Sander, “Effects of thiazolidinediones on blood pressure,” Current Hypertension Reports, vol. 9, no. 4, pp. 332–337, 2007. View at: Google Scholar
  17. P. A. Sarafidis and A. N. Lasaridis, “Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect,” American Journal of Hypertension, vol. 19, no. 6, pp. 646–653, 2006. View at: Publisher Site | Google Scholar
  18. J. A. Dormandy, B. Charbonnel, D. J. A. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macrovascular events): a randomised controlled trial,” The Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at: Publisher Site | Google Scholar
  19. M. Schupp, M. Clemenz, R. Gineste et al., “Molecular characterization of new selective peroxisome proliferator- activated receptor γ modulators with angiotensin receptor blocking activity,” Diabetes, vol. 54, no. 12, pp. 3442–3452, 2005. View at: Publisher Site | Google Scholar
  20. R. A. Sanchez, L. D. Masnatta, C. Pesiney, P. Fischer, and A. J. Ramirez, “Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives,” Journal of Hypertension, vol. 26, no. 12, pp. 2393–2398, 2008. View at: Publisher Site | Google Scholar
  21. I. Imayama, T. Ichiki, K. Inanaga et al., “Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γ,” Cardiovascular Research, vol. 72, no. 1, pp. 184–190, 2006. View at: Publisher Site | Google Scholar
  22. E. R. Blasi, J. Heyen, M. Hemkens, A. McHarg, C. M. Ecelbarger, and S. Tiwari, “Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats,” PPAR Research, vol. 2009, Article ID 237865, 13 pages, 2009. View at: Publisher Site | Google Scholar

Copyright © 2015 Wei Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.